Expand RIGL Menu
RIGL MENU

RIGL Latest Press Releases

-- August 13, 2026 --

Rigel Announces Availability of VEPPANU (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer PRNewswire 8:05 AM

-- August 4, 2026 --

Rigel Reports Second Quarter 2026 Financial Results PRNewswire 4:01 PM

-- July 28, 2026 --

Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results PRNewswire 8:05 AM

-- July 7, 2026 --

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PRNewswire 8:05 AM

-- July 1, 2026 --

Rigel Appoints Board Member Alison L. Hannah, M.D. as Chief Medical Officer PRNewswire 8:05 AM

-- June 16, 2026 --

Rigel Announces Closing of Licensing Agreement for VEPPANU (vepdegestrant) PRNewswire 4:01 PM

-- May 27, 2026 --

Rigel to Present at the Jefferies Global Healthcare Conference PRNewswire 8:05 AM

-- May 21, 2026 --

Rigel Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting and EHA2026 Congress PRNewswire 5:18 PM

-- May 14, 2026 --

Rigel to Present at the 2026 RBC Capital Markets Global Healthcare Conference PRNewswire 8:05 AM

-- May 12, 2026 --

Rigel Enters Exclusive Global Licensing Agreement for VEPPANU (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer PRNewswire 7:00 AM

-- May 5, 2026 --

Rigel Reports First Quarter 2026 Financial Results PRNewswire 4:01 PM

-- April 28, 2026 --

Rigel Announces Conference Call and Webcast to Report First Quarter 2026 Financial Results PRNewswire 8:05 AM

-- April 7, 2026 --

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4) PRNewswire 8:05 AM

-- March 31, 2026 --

Rigel Announces Publication of Final ARROW Clinical Trial Data on GAVRETO (pralsetinib) in Patients with RET+ NSCLC in the Journal of Clinical Oncology PRNewswire 8:05 AM
Market Data Delayed 15 Minutes